Key Takeaways

• Almirall reports a 7.5% YoY increase in Net Sales for H1 2026, reaching €602.7 million.
• EBITDA rose by 23.7% YoY to €150.7 million, driven by strong performance in its European Dermatology business.
• Full-year guidance for 2026 is set at 9-12% Net Sales growth and EBITDA between €270 million and €290 million.

Almirall, S.A., a prominent player in medical dermatology, has announced its financial results for the first half of 2026, showcasing a robust performance. The company achieved Net Sales of €602.7 million, up 7.5% year-on-year, alongside a 23.7% growth in EBITDA to €150.7 million. This solid performance aligns with Almirall’s long-term growth strategy, and the company has reaffirmed its guidance for the full year.

The European Dermatology segment was a key driver of growth, recording an 18.1% increase YoY to €341.9 million, bolstered by successful product launches and a favorable market environment. The biologics portfolio showed noteworthy results, with Ilumetri® netting €125.2 million (up 10.5%) and Ebglyss® experiencing significant growth at €84.5 million (an increase of 88.2%). Additional products, Wynzora® and Klisyri®, contributed positively to the overall performance, reporting increases of 19.3% and 13.9%, respectively.

Almirall’s ongoing commitment to research and development (R&D) is reflected in its pipeline, which includes four active PoC/Phase II studies and plans for two more by the end of 2026, targeting a total of five dermatological diseases. Anticipated readouts for these studies are expected towards the end of 2026. In alignment with its innovation strategy, Almirall has entered a strategic research collaboration with Certest Biotec aimed at developing novel treatments for rare dermatological conditions.

In terms of R&D investment, Almirall has allocated approximately 11.5% of its net sales during the first half of the year. Over the past decade, the company has invested over €1 billion in R&D, underlining its commitment to delivering scientific advancements in dermatology. The current studies focus on conditions such as hidradenitis suppurativa, alopecia areata, and atopic dermatitis, and the company has initiated a Phase I clinical trial for a new bispecific antibody targeting IL-13/OX40L.

Partnerships play a crucial role in Almirall’s success, as evidenced by collaborations with dermatologists, researchers, and organizations like the Barcelona Supercomputing Center (BSC) to leverage supercomputing and AI for enhanced dermatological research. The company aims to deepen scientific exchange and accelerate innovation through these alliances.

As Almirall continues to validate its leadership in medical dermatology, results for the second half of 2026 promise to reflect ongoing advancements. The company maintains an optimistic outlook, forecasting a 9-12% growth in net sales and an EBITDA of €270 million to €290 million for the full year.

For more details on the company and its financials, visit the official Almirall website.

The content above is a summary. For more details, see the source article.